Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRX Pharmaceuticals Inc (NRXP) provides investors and healthcare professionals with critical updates on novel therapies for central nervous system disorders and pulmonary diseases. This page aggregates official press releases, clinical trial developments, and regulatory milestones related to the company’s NMDA platform and ketamine-based treatments.
Visitors gain access to verified information about NRX-100 and NRX-101 – investigational therapies targeting suicidal depression and bipolar disorder – along with strategic initiatives through subsidiary HOPE Therapeutics. The resource prioritizes clarity in explaining complex biopharmaceutical concepts while maintaining scientific precision.
Key content includes updates on Fast Track designations, New Drug Application progress, and innovations in preservative-free drug formulations. The curated news collection serves as a decision-making tool for tracking the company’s progress in addressing unmet medical needs through rigorous clinical research.
Bookmark this page for streamlined access to NRX Pharmaceuticals’ latest developments in interventional psychiatry and small-molecule therapeutics. Check regularly for authoritative updates on pipeline advancements and regulatory strategy execution.
NRx Pharmaceuticals (NASDAQ:NRXP) has re-filed an Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV ketamine formulation, following FDA's approval of its Suitability Petition. The product aims to address the current $750 million ketamine market, projected to reach $3.35 billion globally by 2034.
KETAFREE™ eliminates benzethonium chloride (BZT), a known neurotoxic preservative, and represents a strategic reshoring of drug manufacturing to the US amid current ketamine shortages. The company has filed a citizen's petition to remove BZT from all IV ketamine presentations and has demonstrated long-term stability with its patented preservative-free formulation, manufactured in partnership with Nephron Pharmaceuticals.
This ANDA filing is separate from NRx's ongoing NDA submission for NRX-100 in suicidal ideation treatment, which recently received FDA Fast Track designation.
NRx Pharmaceuticals (NASDAQ:NRXP) received FDA approval for its Suitability Petition regarding KETAFREE™, a preservative-free ketamine product. This approval enables the company to refile its Abbreviated New Drug Application (ANDA) for a single-patient dose formulation that eliminates the toxic preservative Benzethonium Chloride found in current multi-dose vials.
The development aligns with two key administrative policy objectives: reshoring strategically important sterile drugs and removing toxic preservatives from medications. The current ketamine market is valued at $750 million. Beyond KETAFREE™, NRx aims to develop NRX-100, a non-generic ketamine formulation for treating suicidal depression and PTSD under a New Drug Application.
NRx Pharmaceuticals (NASDAQ:NRXP) has completed the acquisition of Dura Medical through its subsidiary HOPE Therapeutics. Dura Medical, along with pending acquisitions of Neurospa TMS and Cohen & Associates, will establish a network of over 8 locations along Florida's West Coast providing interventional psychiatry services.
Dura Medical, founded in 2018 and currently operating in Naples and Ft. Myers, offers comprehensive treatment for depression, PTSD, and chronic pain through advanced procedures including Ketamine Therapy, TMS, Spravato, and Stellate Ganglion Blocks. The company is revenue-generating and EBITDA positive.
Stephen Durand, a US Army Veteran and Dura's founder, will serve as Director of Florida Clinic Operations. The company aims to treat over 10,000 people by 2026 and participates in the Veterans Affairs Community Cares Network to support military veterans.
NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, announced their participation in H.C. Wainwright's 27th Annual Global Investment Conference.
The company's Chairman and CEO, Dr. Jonathan Javitt, will engage in a fireside chat on September 8, 2025, from 4:30 to 5:00 PM ET. The presentation will be available via webcast on the company's investor relations website, with a replay accessible for 30 days after the event.
Management will also be conducting one-on-one meetings with investors during the conference.
NRx Pharmaceuticals (NASDAQ:NRXP) presented at the Global Passion Project symposium, sponsored by Rockefeller Global Family Office, detailing plans for the launch of HOPE Therapeutics clinics in Fall 2025. The company announced Matthew Rockefeller is joining HOPE Therapeutics' Advisory Board.
HOPE Therapeutics will establish a flagship location in Palm Beach, FL, offering a unique one-week residential program combining multiple treatments including ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy to treat suicidal depression, PTSD, and cognitive dysfunction. The company aims for a 90% response rate through this combined treatment approach.
NRx recently secured $8.8 million in funding from biotech investors through a common stock offering with no warrants or variable rate features.
NRx Pharmaceuticals (NASDAQ:NRXP) presented at the Global Passion Project symposium, announcing plans for the Fall 2025 launch of HOPE Therapeutics clinics. The company introduced a groundbreaking residential program combining neuroplastic treatments including ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy for treating suicidal depression, PTSD, and cognitive dysfunction.
The company recently secured $8.8 million in funding from biotech investors through a clean common stock offering. Notable developments include Matthew Rockefeller joining HOPE Therapeutics' Advisory Board and plans for establishing a flagship location in Palm Beach, FL. The combined treatment approach aims to achieve over 90% response rates, significantly higher than the 60% rates typically seen with individual therapies.
NRx Pharmaceuticals (NASDAQ:NRXP) has announced its expanded access policy for NRX-100 (preservative-free ketamine) following FDA's Fast Track designation for treating suicidal ideation in patients with depression, including bipolar depression.
The company will make NRX-100 available through expanded access for patients with serious or life-threatening suicidal depression who haven't responded to current treatments. According to CDC data, approximately 13 million adults consider suicide annually, with one American dying from suicide every 11 minutes.
Eligible patients must meet specific criteria, including having a serious condition unresponsive to approved treatments, and physicians can request access via expandedaccess@nrxpharma.com.
NRx Pharmaceuticals (NASDAQ:NRXP) reported Q2 2025 financial results and significant developments across its drug portfolio. The company received an expanded Fast Track Designation for NRX-100 from the FDA for all depression indications, increasing its addressable market to 13 million Americans. A $6.5 million investment was secured from B Group Capital for approximately 3.9 million shares with a one-year lockup.
Key developments include filing an ANDA for NRX-100, submitting an NDA for NRX-101, and expanding HOPE Therapeutics through strategic acquisitions. The company reported a Q2 2025 net loss of $17.6 million, compared to $7.9 million in Q2 2024, with $2.9 million in cash as of June 30, 2025. HOPE Therapeutics is targeting $100 million in pro-forma revenue by year-end 2025 through clinic acquisitions.
NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, has rescheduled its second quarter 2025 financial results release to August 19, 2025 after market close. The company will host a conference call the following morning on August 20, 2025, at 8:00 AM ET.
The delay is due to the company requiring additional time to compile certain information and recent developments into their Form 10-Q filing. Investors can access the results via press release on the company's website and join the conference call through a webcast or by dialing +1-800-717-1738 (domestic) or +1-646-307-1865 (international).
NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, will release its Q2 2025 financial results on August 14, 2025, after market close.
The company will host a conference call at 4:30 PM ET to discuss corporate updates, financial performance, recent regulatory events, and operational plans. Investors can access the call via webcast on the company's website or by dialing +1-800-717-1738 (domestic) or +1-646-307-1865 (international).
FAQ
What is the current stock price of Nrx Pharmaceuticals (NRXP)?
What is the market cap of Nrx Pharmaceuticals (NRXP)?
